These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 3081460)

  • 1. Double-blind randomized trial of nitroderm TTS in the treatment of Raynaud's phenomenon.
    Nahir AM; Schapira D; Scharf Y
    Isr J Med Sci; 1986 Feb; 22(2):139-42. PubMed ID: 3081460
    [No Abstract]   [Full Text] [Related]  

  • 2. MQX-503, a novel formulation of nitroglycerin, improves the severity of Raynaud's phenomenon: a randomized, controlled trial.
    Chung L; Shapiro L; Fiorentino D; Baron M; Shanahan J; Sule S; Hsu V; Rothfield N; Steen V; Martin RW; Smith E; Mayes M; Simms R; Pope J; Kahaleh B; Csuka ME; Gruber B; Collier D; Sweiss N; Gilbert A; Dechow FJ; Gregory J; Wigley FM
    Arthritis Rheum; 2009 Mar; 60(3):870-7. PubMed ID: 19248104
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Topical nitroglycerin ointment in Raynaud's phenomenon.
    Fischer M; Reinhold B; Falck H; Török M; Alexander K
    Z Kardiol; 1985 May; 74(5):298-302. PubMed ID: 3925656
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A double blind placebo controlled crossover randomized trial of diltiazem in Raynaud's phenomenon.
    Rhedda A; McCans J; Willan AR; Ford PM
    J Rheumatol; 1985 Aug; 12(4):724-7. PubMed ID: 3903157
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Nicardipine in the treatment of Raynaud's phenomenon].
    Kahan A; Amor B; Menkès CJ
    Rev Rhum Mal Osteoartic; 1987 Jun; 54(6):487-90. PubMed ID: 3303287
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nicardipine for the treatment of Raynaud's phenomena: a double blind crossover trial of a new calcium entry blocker.
    Rupp PA; Mellinger S; Kohler J; Dorsey JK; Furst DE
    J Rheumatol; 1987 Aug; 14(4):745-50. PubMed ID: 3312603
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Controlled double-blind trial of nifedipine in the treatment of Raynaud's phenomenon.
    Rodeheffer RJ; Rommer JA; Wigley F; Smith CR
    N Engl J Med; 1983 Apr; 308(15):880-3. PubMed ID: 6339921
    [No Abstract]   [Full Text] [Related]  

  • 8. Effect of ketanserin on Raynaud's phenomenon in progressive systemic sclerosis: a double-blind trial.
    Lukác J; Rovenský J; Tauchmannová H; Zitnan D
    Drugs Exp Clin Res; 1985; 11(9):659-63. PubMed ID: 3916837
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Raynaud's disease treated with captopril (Capoten). A randomized double-blind cross-over study].
    Madsen JL; Hvidt S
    Ugeskr Laeger; 1984 Sep; 146(36):2695-7. PubMed ID: 6393495
    [No Abstract]   [Full Text] [Related]  

  • 10. [A double-blind clinical trial of a topical preparation with a base of biochemical precursors of glucosaminoglycan (GAG) in patients suffering from Raynaud's disease].
    Signorini GP
    Boll Chim Farm; 1986 Oct; 125(10):103S-110S. PubMed ID: 3551995
    [No Abstract]   [Full Text] [Related]  

  • 11. Nitroderm TTS in exercise-induced angina pectoris--a randomized double-blind study.
    Colombo G; Favini G; Aglieri S; Pollavini G; de Vita C
    Int J Clin Pharmacol Ther Toxicol; 1985 Apr; 23(4):211-4. PubMed ID: 3922903
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A double-blind controlled trial of low dose acetylsalicylic acid and dipyridamole in the treatment of Raynaud's phenomenon.
    van der Meer J; Wouda AA; Kallenberg CG; Wesseling H
    Vasa Suppl; 1987; 18():71-5. PubMed ID: 3299819
    [No Abstract]   [Full Text] [Related]  

  • 13. [Treatment of systemic scleroderma with ketanserin. Randomized, double-blind 6-months study of 27 cases].
    Cadranel J; Blétry O; Guillevin L; Lacombe C; Fraitag B; Duloroy J; Mouthon JM; Godeau P
    Ann Med Interne (Paris); 1986; 137(3):260-3. PubMed ID: 3532900
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nicardipine in the treatment of Raynaud's phenomenon: a randomized double-blind trial.
    Kahan A; Amor B; Menkès CJ; Weber S; Guérin F; Degeorges M
    Angiology; 1987 Apr; 38(4):333-7. PubMed ID: 3555175
    [TBL] [Abstract][Full Text] [Related]  

  • 15. DIAS rounds. Nifedipine and prazosin in Raynaud's phenomenon.
    Pisenti L; Hart LL
    Drug Intell Clin Pharm; 1984 Mar; 18(3):213-4. PubMed ID: 6365494
    [No Abstract]   [Full Text] [Related]  

  • 16. Sustained-release transdermal glyceryl trinitrate patches as a treatment for primary and secondary Raynaud's phenomenon.
    Teh LS; Manning J; Moore T; Tully MP; O'Reilly D; Jayson MI
    Br J Rheumatol; 1995 Jul; 34(7):636-41. PubMed ID: 7670782
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A double blind trial of UK-38,485, an orally active thromboxane synthetase inhibitor, in the treatment of Raynaud's syndrome.
    Rustin MH; Grimes SM; Kovacs IB; Cooke ED; Bowcock SA; Sowemimo-Coker SO; Turner P; Kirby JD
    Eur J Clin Pharmacol; 1984; 27(1):61-5. PubMed ID: 6386490
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inefficacy of diltiazem in the treatment of Raynaud's phenomenon with associated connective tissue disease: a double blind placebo controlled study.
    da Costa J; Gomes JA; Espirito Santo J; Queirós M
    J Rheumatol; 1987 Aug; 14(4):858-9. PubMed ID: 3668998
    [No Abstract]   [Full Text] [Related]  

  • 19. Effect of the calcium channel blocker nifedipine on Raynaud's phenomenon. A controlled double blind trial.
    Sauza J; Kraus A; González-Amaro R; Alarcón-Segovia D
    J Rheumatol; 1984 Jun; 11(3):362-4. PubMed ID: 6376801
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Trial of a new drug in Raynaud's disease. Clinical and thermographic control].
    Dumoulin J
    Electrodiagn Ther; 1981; 18(4):168-74. PubMed ID: 6279383
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.